Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Tildrakizumab |
Trade Name | Ilumya |
Synonyms | MK-3222 |
Drug Descriptions |
Ilumya (tildrakizumab) is a monoclonal antibody that binds to the p19 subunit of IL-23 and prevents interaction with the IL-23 receptor, potentially leading to decreased release of proinflammatory cytokines (PMID: 31548750). Ilumya (tildrakizumab) is FDA approved for use in patients with moderate-to-severe plaque psoriasis (FDA.gov). |
DrugClasses | |
CAS Registry Number | 1326244-10-3 |
NCIT ID | C152627 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Abiraterone + Tildrakizumab | Abiraterone Tildrakizumab | 0 | 1 |
Tildrakizumab | Tildrakizumab | 0 | 0 |